Paper Details

  1. Home
  2. Paper Details

A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.

Author: DemuraMamiko, EsakaNaoki, FujiiHiroyuki, HamadaHiroshige, HaradaNaohiko, HiraiYuichiro, InoueShuji, KagayaTakashi, KatoMototsugu, KuboKimitoshi, KuwaiToshio, MabeKatsuhiro, MatsudaSoichiro, MatsumotoMio, MoriHideki, SakakibaraYuko, SasakiYoshihiro, ToyokawaTatsuya, WatanabeNoriko, YamashitaHaruhiro

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the effectiveness of vonoprazan, administered every second day, with proton pump inhibitors (PPIs) in the maintenance therapy of erosive GERD. The results suggested that vonoprazan was superior to PPIs in this setting.
Paper Details　
Original Abstract of the Article :
Vonoprazan is a potassium competitive acid blocker used to treat erosive gastroesophageal reflux disease (GERD) with stronger, more stable acid-suppressing effects than proton pump inhibitors (PPIs). This study clarified the usefulness and superiority of vonoprazan administered every second day over...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00535-022-01850-2

データ提供：米国国立医学図書館（NLM）

Vonoprazan: A New Era in Erosive GERD Maintenance Therapy

Erosive gastroesophageal reflux disease (GERD) is a chronic condition characterized by acid reflux that damages the lining of the esophagus. This research explores the effectiveness of vonoprazan, a potassium-competitive acid blocker, in maintaining remission of erosive GERD. The study investigates the effectiveness of vonoprazan administered every second day compared to proton pump inhibitors (PPIs) in a randomized cross-over design. The researchers aimed to determine whether vonoprazan offers a superior and more convenient treatment option for maintaining remission of erosive GERD.

Vonoprazan: A Promising Alternative for GERD Maintenance Therapy

This study suggests that vonoprazan administered every second day could be a valuable alternative to PPIs for maintaining remission of erosive GERD. It highlights the potential for vonoprazan to provide a more convenient and effective treatment option for patients with this chronic condition.

Navigating GERD: A Search for Effective and Convenient Treatment

This research underscores the ongoing search for effective and convenient treatments for GERD. Vonoprazan, with its unique mechanism of action and potential for every-other-day dosing, offers a promising new approach to managing this common condition.

Dr. Camel's Conclusion

GERD can feel like a burning desert, with acid reflux scorching the lining of the esophagus. This research offers a potential oasis in this fiery landscape, highlighting the effectiveness of vonoprazan in maintaining remission of erosive GERD. Vonoprazan, with its convenient dosing schedule, could provide a welcome respite for those seeking to manage their GERD symptoms and reclaim a sense of comfort. Let's continue to explore new avenues for treating GERD, ensuring that all travelers through this desert can experience relief and well-being.

Date :
  1. Date Completed 2022-03-23
  2. Date Revised 2022-03-23
Further Info :

Pubmed ID

35092498

DOI: Digital Object Identifier

10.1007/s00535-022-01850-2

Related Literature

Article Analysis
・Effects of vonoprazan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.